Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Acadra; AICA riboside; ARA 100; Arasine; ATH 001; GP 1 110; Protara; SCH 900395

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AdvanCell; SICOR
  • Developer Advancell; Groupe Francophone des Myelodysplasies; Merck & Co; SICOR
  • Class Amides; Antineoplastics; Antiplatelets; Imidazoles; Ribonucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; Platelet aggregation inhibitors; Purinergic P1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Discontinued Asthma; Diabetes mellitus; Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
  • 07 Nov 2016 AdvanCell terminates a phase I/II trial for Myelodysplastic syndromes (Treatment-resistant, Recurrent) in France prior to November 2016 (NCT01813838)
  • 16 Sep 2015 No recent reports on development identified - Phase-I/II for Chronic lymphocytic leukaemia (Second-line therapy or greater) in Belgium, France and Spain (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top